Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHAM
- Development stage
- Phase 1
- Lead developer
- Cornerstone Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CHAM is a combination therapy regimen primarily investigated for relapsed/refractory Acute Myeloid Leukemia (AML). It consists of CPI-613 (devimistat), high-dose cytarabine, and mitoxantrone. CPI-613 (devimistat) is an investigational drug designed to target the altered energy metabolism and processes for the production of ATP and essential bio-intermediates characteristic of cancer cells. Cytarabine is an antimetabolite that interferes with DNA synthesis, while mitoxantrone is a topoisomerase II inhibitor. This combination aims to improve complete remission rates in older patients with AML.
- Other names
- CPI-613 + Cytarabine + MitoxantroneDevimistat + Cytarabine + Mitoxantrone
02
Targets
PDH (Pyruvate dehydrogenase complex)α-KGDH (Alpha-ketoglutarate dehydrogenase complex)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CHAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHAM.